#1 Clinical Trials Search in Europe

Rifaximin

Rifaximin, a non-systemic antibiotic, is being studied in several clinical trials for its potential benefits in treating various medical conditions. These trials aim to evaluate the efficacy and safety of rifaximin in managing liver diseases, gastrointestinal disorders, and other health issues. The research focuses on understanding how rifaximin affects bacterial overgrowth, intestinal permeability, and overall patient outcomes.

Table of Contents

What is Rifaximin?

Rifaximin is an antibiotic medication that is primarily used to treat various gastrointestinal conditions. It is also known by its brand name Xifaxan[1]. Unlike many other antibiotics, rifaximin is considered a non-systemic antibiotic, which means it primarily acts within the gut and is not significantly absorbed into the bloodstream[2]. This unique characteristic allows it to target bacteria in the intestines while minimizing potential side effects in other parts of the body.

Conditions Treated with Rifaximin

Rifaximin is used to treat several gastrointestinal conditions, including:

  • Irritable Bowel Syndrome (IBS): Particularly for diarrhea-predominant IBS (IBS-D) and mixed IBS (IBS-M)[3].
  • Hepatic Encephalopathy: A brain condition that occurs when the liver is unable to remove toxins from the blood[4].
  • Bacterial Vaginosis: An infection caused by an imbalance of bacteria in the vagina[5].
  • Small Intestinal Bacterial Overgrowth (SIBO): A condition where excessive bacteria grow in the small intestine[3].
  • Cirrhosis: A late stage of scarring of the liver[6].

How Rifaximin Works

Rifaximin works by reducing the number of harmful bacteria in the intestines. It does this by inhibiting bacterial protein synthesis, which prevents the bacteria from growing and multiplying[2]. This action can help alleviate symptoms associated with various gastrointestinal conditions, such as diarrhea, abdominal pain, and bloating.

In the case of hepatic encephalopathy, rifaximin helps by reducing the production of ammonia in the gut. Ammonia is a toxic substance that can build up in the blood when the liver is not functioning properly, leading to brain dysfunction[4].

Dosage and Administration

The dosage and duration of rifaximin treatment can vary depending on the condition being treated. Some common dosages include:

  • For IBS: 550 mg taken orally three times a day for 14 days[3].
  • For hepatic encephalopathy: 550 mg taken orally twice a day[4].
  • For bacterial vaginosis: Dosages may vary, but one study investigated 25 mg and 100 mg vaginal tablets administered once a day for 5 days[5].

It’s important to note that rifaximin should always be taken as prescribed by your healthcare provider.

Ongoing Research and Potential New Uses

Researchers are continuously exploring new potential uses for rifaximin. Some areas of ongoing research include:

  • Primary Sclerosing Cholangitis (PSC): A study is investigating the potential benefits of rifaximin in patients with this chronic liver disease[7].
  • Sickle Cell Disease: Researchers are studying whether rifaximin can modify the disease course in patients with sickle cell disease by altering the gut microbiome[8].
  • Monoclonal Gammopathy: A pilot study is evaluating the effects of rifaximin on patients with this blood disorder characterized by abnormal protein production[9].
  • Sleep Disorders in Hepatic Encephalopathy: Researchers are investigating whether rifaximin can improve sleep quality in patients with hepatic encephalopathy[4].

Potential Side Effects

While rifaximin is generally well-tolerated due to its limited systemic absorption, some patients may experience side effects. Common side effects may include:

  • Nausea
  • Vomiting
  • Diarrhea
  • Abdominal discomfort
  • Headache

It’s important to report any unusual or severe side effects to your healthcare provider[8].

Condition Rifaximin Dosage Duration Primary Outcome Measures
Liver Cirrhosis Various doses (40mg to 160mg) 24 weeks Time to all-cause mortality or hospitalization
Hepatic Encephalopathy 550mg twice daily 2 weeks Percentage of Slow Wave Sleep and REM Sleep
Irritable Bowel Syndrome 550mg three times daily 14 days Change in rectal sensitivity
Sickle Cell Disease 550mg twice daily 12 months Changes in annual rate of hospital admissions
Monoclonal Gammopathy Not specified 2 weeks Reduction in clonal immunoglobulin by > 25%
HIV and Hepatitis C 550mg twice daily 1 year Liver fibrosis progression

FAQ

  • What is rifaximin and how does it work? Rifaximin is a non-systemic antibiotic, meaning it acts primarily in the gut without being absorbed into the bloodstream. It works by reducing harmful bacteria in the intestines, which can help manage various conditions related to gut health and liver function.
  • In which medical conditions is rifaximin being studied? Rifaximin is being studied in several conditions, including liver cirrhosis, hepatic encephalopathy, irritable bowel syndrome, small intestinal bacterial overgrowth, sickle cell disease, and monoclonal gammopathy.
  • How is rifaximin administered in these clinical trials? In most trials, rifaximin is administered orally, typically as tablets. The dosage and duration vary depending on the study, but common doses include 550 mg twice daily or three times daily for periods ranging from 2 weeks to 12 months.
  • What are some potential benefits of rifaximin being investigated? Researchers are investigating rifaximin's potential to reduce complications in liver cirrhosis, improve brain function in hepatic encephalopathy, decrease abdominal pain in irritable bowel syndrome, reduce hospital admissions in sickle cell disease, and possibly slow the progression of monoclonal gammopathy.
  • Are there any side effects associated with rifaximin in these trials? While rifaximin is generally well-tolerated, researchers are monitoring for potential side effects. These may include nausea, vomiting, diarrhea, and abdominal discomfort. The trials also assess long-term safety, especially in patients taking other medications.

Ongoing Clinical Trials on Rifaximin

  • Safety and feasibility study of fecal microbiota transplant in stage II-III non-small cell lung cancer patients treated with durvalumab, carboplatin, paclitaxel and rifaximin

    Recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Spain

  • Study of apomorphine and rifaximin for Parkinson’s disease patients with reduced levodopa effectiveness

    Recruiting

    2 1 1
    Investigated diseases:
    Investigated drugs:
    The Netherlands

  • Study on Preventing Hepatic Encephalopathy with Rifaximin and Lactulose in Patients with Alcoholic Liver Cirrhosis Undergoing TIPS Placement

    Recruiting

    3 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium The Netherlands

  • A study to evaluate the effects of rifaximin in patients with opioid use disorder

    Not yet recruiting

    2 1 1
    Investigated diseases:
    Investigated drugs:
    Italy

  • Study on the Effects of Rifaximin on Stress and Fear Responses in Healthy Men

    Not recruiting

    2 1 1
    Investigated drugs:
    Belgium

  • Study on Rifaximin for Delaying Hepatic Encephalopathy in Cirrhosis Patients

    Not recruiting

    3 1
    Investigated diseases:
    Investigated drugs:
    Belgium Bulgaria France Germany Hungary Italy +2

Glossary

  • Hepatic Encephalopathy: A condition that affects the brain due to advanced liver disease, causing confusion, altered level of consciousness, and potentially coma.
  • Liver Cirrhosis: A late stage of scarring (fibrosis) of the liver caused by many forms of liver diseases and conditions, such as hepatitis and chronic alcoholism.
  • Small Intestinal Bacterial Overgrowth (SIBO): A condition where excessive bacteria grow in the small intestine, potentially causing digestive symptoms and malnutrition.
  • Irritable Bowel Syndrome (IBS): A common disorder that affects the large intestine, causing abdominal pain, cramping, bloating, and changes in bowel movements.
  • Monoclonal Gammopathy: A condition in which abnormal proteins are found in the blood, which can be a precursor to certain blood cancers.
  • Sickle Cell Disease: An inherited red blood cell disorder where blood cells become crescent-shaped and can block small blood vessels, causing pain and organ damage.
  • Visceral Hypersensitivity: Increased sensitivity of internal organs to stimuli, often associated with chronic pain conditions like IBS.
  • Microbiome: The collection of all microbes, such as bacteria, fungi, and viruses, that naturally live on and in our bodies.
  • Transient Elastography: A non-invasive method to assess liver stiffness, which is often used to evaluate the progression of liver fibrosis.

References

  1. https://clinicaltrials.gov/study/NCT01345175
  2. https://clinicaltrials.gov/study/NCT01904409
  3. https://clinicaltrials.gov/study/NCT03462966
  4. https://clinicaltrials.gov/study/NCT02163837
  5. https://clinicaltrials.gov/study/NCT02376972
  6. https://clinicaltrials.gov/study/NCT02931123
  7. https://clinicaltrials.gov/study/NCT01695174
  8. https://clinicaltrials.gov/study/NCT03719729
  9. https://clinicaltrials.gov/study/NCT03820817